Sphingosine 1-phosphate and lysophosphatidic acid receptors: Agonist and antagonist binding and progress toward development of receptor-specific ligands

Seminars in Cell and Developmental Biology

Volumn 15, Issue 5, 2004, Pages 467-476

  Parrill, Abby L ^a   Sardar, Vineet M ^a   Yuan, Hongbin ^a  

^a UNIVERSITY OF MEMPHIS   (United States)

Author keywords

Computational model; Lysophosphatidic acid; Receptor structure; Sphingosine 1 phosphate; Structure activity relationship

Indexed keywords

2 (3 HEPTYLPHENYL)THIAZOLIDINE 4 CARBOXYLIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 [4 (2 CARBAZOL 9 YLETHOXY)PHENYL] 2 ETHOXYPROPANOIC ACID; ANTIDIABETIC AGENT; CELL NUCLEUS RECEPTOR; CELL SURFACE RECEPTOR; DIOCTYLGLYCEROLPYROPHOSPHATE; FARGLITAZAR; FINGOLIMOD; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR; GW 409544; IMMUNOSUPPRESSIVE AGENT; JTE 013; KI 16425; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARTIAL AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROPIONIC ACID DERIVATIVE; RAGAGLITAZAR; RECEPTOR BLOCKING AGENT; ROSIGLITAZONE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TESAGLITAZAR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VPC 12249;

CRYSTALLOGRAPHY; DRUG EFFECT; DRUG SELECTIVITY; HUMAN; HYDROPHOBICITY; KIDNEY ISCHEMIA; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MOLECULAR RECOGNITION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN STRUCTURE; RECEPTOR AFFINITY; RECEPTOR BINDING; REPERFUSION INJURY; REVIEW; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION;

EID: 3242696731     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2004.05.006     Document Type: Article

References (106)

1. Mills G.B., Moolenaar W.H. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer. 3:2003;582-591
2. Spiegel S., Milstien S. Exogenous and intracellularly generated sphingosine 1-phosphate can regulate cellular processes by divergent pathways. Biochem. Soc. Trans. 31:2003;1216-1219
3. Hla T. Signaling and biological actions of sphingosine 1-phosphate. Pharmacol. Res. 47:2003;401-407
4. Spiegel S., Kolesnick R. Sphingosine 1-phosphate as a therapeutic agent. Leukemia. 16:2002;1596-1602
5. Osborne N., Stainier D.Y. Lipid receptors in cardiovascular development. Annu. Rev. Physiol. 65:2003;23-43
6. Brinkmann V., Davis M.D., Heise C.E., Albert R., Cottens S., Hof R., et al. The immune modulator, FTY720, targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277:2002;21453-21457
7. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., et al. Alteration of lymphocyte trafficking by sphingosine 1-phosphate receptor agonists. Science. 296:2002;346-349
8. Yanagawa Y., Sugahara K., Kataoka H., Kawaguchi T., Masubuchi Y., Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J. Immunol. 160:1998;5493-5499
9. Chiba K., Yanagawa Y., Masubuchi Y., Kataoka H., Kawaguchi T., Ohtsuki M., et al. FTY720, a novel immunosuppressent, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. 160:1998;5037-5044
10. Suzuki S., Enosawa S., Kakefuda T., Shinomiya T., Amari M., Naoe S., et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation. 61:1996;200-205
11. Brinkmann V., Pinschewer D.D., Feng L., Chen S. FTY720: altered lymphocyte traffic results in allograft protection. Transplantation. 72:2001;764-769
12. Suzuki S. FTY720: mechanisms of action and its effect on organ transplantation (review). Transplant Proc. 31:1999;2779-2782
13. Deng W., Balazs L., Wang D.A., Van Middlesworth L., Tigyi G., Johnson L.R. Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation- and chemotherapy-induced apoptosis. Gastroenterology. 123:2002;206-216
14. Deng W., Wang D.A., Gosmanova E., Johnson L.R., Tigyi G. LPA protects intestinal epithelial cells from apoptosis by inhibiting the mitochondrial pathway. Am. J. Physiol. Gastrointest. Liver Physiol. 284:2003;G821-G829
15. Tilly J.L., Kolesnick R.N. Sphingolipids, apoptosis, cancer treatments and the ovary: investigating a crime against female fertility. Biochim. Biophys. Acta. 1585:2002;135-138
16. Uhlenbrock K., Gassenhuber H., Kostenis E. Sphingosine 1-phosphate is a ligand of the human GPR3, GPR6 and GPR12 family of constitutively active G protein-coupled receptors. Cell. Signall. 14:2002;941-953
17. 2+ release by activating the sphingosine-kinase pathway. Biochem. Biophys. Res. Commun. 311:2003;329-336
18. Ignatov A., Lintzel J., Hermans-Borgmeyer I., Kreienkamp H., Joost P., Thomsen S., et al. Role of the G-protein-coupled receptor GPR12 as high-affinity receptor for sphingosylphosphorylcholine and its expression and function in brain development. J. Neurosci. 23:2003;907-914
19. Lee M.-J., Van Brocklyn J.R., Thangada S., Liu C.H., Hand A.R., Menzeleev R., et al. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science. 279:1998;1552-1555
20. Hla T., Maciag T. An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. J. Biol. Chem. 265:1990;9306-9313
21. MacLennan A.J., Browe C.S., Gaskin A.A., Lado D.C., Shaw G. Cloning and characterization of a putative G-protein coupled receptor potentially involved in development. Mol. Cell Neurosci. 5:1994;201-209
22. An S., Bleu T., Huang W., Hallmark O.G., Coughlin S.R., Goetzl E.J. Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids. FEBS Lett. 417:1997;279-282
23. Yamaguchi F., Tokuda M., Hatase O., Brenner S. Molecular cloning of the novel human G protein-coupled receptor (GPCR) gene mapped on chromosone 9. Biochem. Biophys. Res. Commun. 227:1996;608-614
24. Gräler M.H., Bernhardt G., Lipp M. EDG6, a novel G-protein-coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue. Genomics. 53:1998;164-169
25. Malek R.L., Toman R.E., Edsall L.C., Wong S., Chiu J., Letterle C.A., et al. Nrg-1 belongs to the endothelial differentiation gene family of G protein-coupled sphingosine-1-phosphate receptors. J. Biol. Chem. 276:2001;5692-5699
26. Glickman M., Malek R.L., Kwitek-Black A.E., Jacob H.J., Lee N.H. Molecular cloning, tissue-specific expression, and chromosomal localization of a novel nerve growth factor-regulated G-protein- coupled receptor, nrg-1. Mol. Cell. Neurosci. 14:1999;141-152
27. Hecht J.H., Weiner J.A., Post S.R., Chun J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J. Cell Biol. 135:1996;1071-1083
28. An S., Dickens M.A., Bleu T., Hallmark O.G., Goetzl E.J. Molecular cloning of the human Edg2 protein and its identification as a functional cellular receptor for lysophosphatidic acid. Biochem. Biophys. Res. Commun. 231:1997;619-622
29. An S., Bleu T., Hallmark O.G., Goetzl E.J. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J. Biol. Chem. 273:1998;7906-7910
30. Fitzgerald L.R., Dytko G.M., Sarau H.M., Mannan I.J., Ellis C., Lane P.A., et al. Identification of an EDG7 variant, HOFNH30, a G-protein-coupled receptor for lysophosphatidic acid. Biochem. Biophys. Res. Commun. 273:2000;805-810
31. Bandoh K., Aoki J., Hosono H., Kobayashi S., Kobayashi T., Murakami-Murofushi K., et al. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J. Biol. Chem. 274:1999;27776-27785
32. Im D.-S., Heise C.E., Harding M.A., George S.R., O'Dowd B.F., Theodorescu D., et al. Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. Mol. Pharmacol. 57:2000;753-759
33. Noguchi K., Ishii S., Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J. Biol. Chem. 278:2003;25600-25606
34. Niedernberg A., Tunaru S., Blaukat A., Ardati A., Kostenis E. Sphingosine 1-phosphate and dioleoylphosphatidic acid are low affinity agonists for the orphan receptor GPR63. Cell. Signall. 15:2003;435-446
35. Guo Z., Liliom K., Fischer D.J., Bathurst I.C., Tomei L.D., Kiefer M.C., et al. Molecular cloning of a high-affinity receptor for the growth factor-like lipid mediator lysophosphatidic acid from Xenopus oocytes. Proc. Natl. Acad. Sci. U.S.A. 93:1996;14367-14372
36. McIntyre T.M., Pontsler A.V., Silva A.R., St Hilaire A., Xu Y., Hinshaw J.C., et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc. Natl. Acad. Sci. U.S.A. 100:2003;131-136
37. Gobeil F. Jr., Bernier S.G., Vazquez-Tello A., Brault S., Beauchamp M.H., Quiniou C., et al. Modulation of pro-inflammatory gene expression by nuclear lysophosphatidic acid receptor type-1. J. Biol. Chem. 278:2003;38875-38883
38. Niedernberg A., Scherer C.R., Busch A.E., Kostenis E. Comparative analysis of human and rat S1P5 (edg8): differential expression profiles and sensitivities to antagonists. Biochem. Pharmacol. 64:2002;1243-1250
39. Van Brocklyn J.R., Tu Z., Edsall L.C., Schmidt R.R., Spiegel S. Sphingosine 1-phosphate-induced cell rounding and neurite retraction are mediated by the G protein-coupled receptor H218. J. Biol. Chem. 274:1999;4626-4632
40. Sanna MG, Liao J, Jo E, Alfonso C, Ahn M, Peterson MS, et al. Distinct S1P receptor subtypes S1P1 and S1P3 respectively regulate lymphocyte recirculation and heart rate. J. Biol. Chem 2004;279(14):13839-48.
41. i-coupled receptor Edg-1 and intracellular to regulate proliferation and survival. J. Cell Biol. 142:1998;229-240
42. Van Brocklyn J.R., Gräler M.H., Bernhardt G., Hobson J.P., Spiegel S. Sphingosine-1-phosphate is a ligand for the G protein-coupled receptor EDG-6. Blood. 95:2000;2624-2629
43. 2+ mobilization, ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition. J. Biol. Chem. 273:1998;27104-27110
44. Lim H., Oh Y., Suh P., Chung S. Syntheses of sphingosine-1-phosphate stereoisomers and analogues and their interaction with EDG receptors. Bioorg. Med. Chem. Lett. 13:2003;237-240
45. Im D.-S., Clemens J., Macdonald T.L., Lynch K.R. Characterization of the human and mouse sphingosine 1-phosphate receptor, S1P5 (Edg-8): structure-activity relationship of sphingosine 1-phosphate receptors. Biochemistry. 40:2001;14053-14060
46. Hakogi T., Shigenari T., Katsumara S., Sano T., Kohno T., Igarashi Y. Synthesis of fluorescence-labeled sphingosine and sphingosine 1-phosphate; effective tools for sphingosine and sphingosine 1-phosphate behavior. Bioorg. Med. Chem. Lett. 13:2003;661-664
47. Lu X., Cseh S., Byun H.S., Tigyi G., Bittman R. Total synthesis of two photoactivatable analogues of the growth-factor-like mediator sphingosine 1-phosphate: differential interaction with protein targets. J. Org. Chem. 68:2003;7046-7050
48. Kiuchi M., Adachi K., Kohara T., Minoguchi M., Hanano T., Aoiki Y., et al. Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols. J. Med. Chem. 43:2000;2946-2961
49. Clemens J.J., Davis M.D., Lynch K.R., Macdonald T.L. Synthesis of para-alkyl aryl amide analogues of sphingosine-1-phosphate: discovery of potent S1P receptor agonists. Bioorg. Med. Chem. Lett. 13:2003;3401-3404
50. Brinkmann V., Lynch K.R. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr. Opin. Immunol. 14:2002;569-575
51. Holdsworth G, Osborne DA, Pham TT, Fells JI, Hutchinson G, Milligan G, et al. A single amino acid determines preference between phospholipids and reveals length restriction for activation of the S1P4 receptor, submitted for publication.
52. Tigyi G., Parrill A.L. Molecular mechanisms of lysophosphatidic acid action. Prog. Lipid Res. 42:2003;498-526
53. Xu Y., Qian L., Prestwich G.D. Synthesis of monofluorinated analogues of lysophosphatidic acid. J. Org. Chem. 68:2003;5320-5330
54. 3 receptor. J. Biol. Chem. 278:2003;11962-11969
55. 3 receptor-selective agonist activity. J. Med. Chem. 46:2003;5575-5578
56. Yokoyama K., Baker D.L., Virag T., Liliom K., Byun H., Tigyi G., et al. Stereochemical properties of lysophosphatidic acid receptor activation and metabolism. Biochim. Biophys. Acta. 1582:2002;295-308
57. 3 receptor antagonist. Mol. Pharmacol. 60:2001;1173-1180
58. Bandoh K., Aoki J., Taira A., Tsujimoto M., Arai H., Inoue K. Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species: structure-activity relationship of cloned LPA receptors. FEBS Lett. 478:2000;159-165
59. Qian L., Xu Y., Arai H., Aoki J., McIntyre T.M., Prestwich G.D. Synthesis of migration-resistant hydroxyethoxy analogues of lysophosphatidic acid. Org. Lett. 5:2003;4685-4688
60. Corton J.C., Anderson S.P., Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu. Rev. Pharmacol. Toxicol. 40:2000;491-518
61. Davies S.S., Pontsler A.V., Marathe G.K., Harrison K.A., Murphy R.C., Hinshaw J.C., et al. Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists. J. Biol. Chem. 276:2001;16015-16023
62. Xu Y., Prestwich G.D. Concise synthesis of acyl migration-blocked 1,1-difluorinated analogues of lysophosphatidic acid. J. Org. Chem. 67:2002;7158-7161
63. Xu Y., Qian L., Pontsler A.V., McIntyre T.M., Prestwich G.D. Synthesis of difluoromethyl-substituted lysophosphatidic acid analogues. Tetrahedron. 60:2004;47-53
64. Pierce K.L., Premont R.T., Lefkowitz R.J. Seven-transmembrane receptors. Nat. Rev. 3:2002;639-650
65. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science. 289:2000;739-745
66. Sardar V.M., Bautista D.L., Fischer D.J., Yokoyama K., Nusser N., Virag T., et al. Molecular basis for lysophosphatidic acid receptor antagonist selectivity. Biochim. Biophys. Acta. 1582:2002;309-317
67. 1 (EDG2) phospholipid growth factor receptors. J. Biol. Chem. 276:2001;49213-49220
68. Virag T., Elrod D.B., Liliom K., Sardar V.M., Parrill A.L., Yokoyama K., et al. Fatty alcohol phosphates are subtype-selective agonists and antagonists of LPA receptors. Mol. Pharmacol. 63:2003;1032-1042
69. Parrill A.L., Wang D.-A., Bautista D.L., Van Brocklyn J.R., Lorincz Z., Fischer D.J., et al. Identification of Edg1 receptor residues that recognize sphingosine 1-phosphate. J. Biol. Chem. 275:2000;39379-39384
70. Parrill AL, Baker DL, Wang D, Fischer DJ, Bautista DL, van Brocklyn J, et al. Structural features of EDG1 receptor-ligand complexes revealed by computational modeling and mutagenesis. In: Goetzl EJ, Lynch KR, editors. Lysophospholipids and eicosanoids in biology and pathophysiology. Ann N Y Acad Sci, vol. 905; 2000. p. 330-9.
71. Bautista D.L., Baker D.L., Wang D., Fischer D.J., Van Brocklyn J., Spiegel S., et al. Dynamic modeling of EDG1 receptor structural changes induced by site-directed mutations. J. Mol. Struct. THEOCHEM. 529:2000;219-224
72. Vaidehi N., Floriano W.B., Trabanino R., Hall S.E., Freddolino P., Choi E.J., et al. Prediction of structure and function of G protein-coupled receptors. Proc. Natl. Acad. Sci. U.S.A. 99:2002;12622-12627
73. Ballesteros JA, Weinstein H. Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors. In: Conn PM, Sealfon SC, editors. Methods in neurosciences, vol. 25. Academic Press; 1995. p. 366-428.
74. Cronet P., Petersen J.F., Folmer R., Blomberg N., Sjoblom K., Karlsson U., et al. Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242 ligand selectivity and agonist activation in the PPAR family. Structure (Camb). 9:2001;699-706
75. Xu H.E., Lambert M.H., Montana V.G., Plunket K.D., Moore L.B., Collins J.L., et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U.S.A. 98:2001;13919-13924
76. Gampe R.T. Jr., Montana V.G., Lambert M.H., Miller A.B., Bledsoe R.K., Milburn M.V., et al. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell. 5:2000;545-555
77. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 395:1998;137-143
78. Sauerberg P., Pettersson I., Jeppesen L., Bury P.S., Mogensen J.P., Wassermann K., et al. Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. J. Med. Chem. 45:2002;789-804
79. Ebdrup S., Pettersson I., Rasmussen H.B., Deussen H.J., Frost Jensen A., Mortensen S.B., et al. Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. J. Med. Chem. 46:2003;1306-1317
80. Oberfield J.L., Collins J.L., Holmes C.P., Goreham D.M., Cooper J.P., Cobb J.E., et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc. Natl. Acad. Sci. U.S.A. 96:1999;6102-6106
81. Yu C., Chen L., Luo H., Chen J., Cheng F., Gui C., et al. Binding analyses between Human PPARgamma-LBD and ligands. Eur. J. Biochem. 271:2004;386-397
82. Kawasaki H, Ozawa K, Yamamoto K. Pyrazolopyridine compounds and use thereof as drugs. Patent 2001. WO 01/98301 A1.
83. Osada M., Yatomi Y., Ohmori T., Ikeda H., Ozaki Y. Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist. Biochem. Biophys. Res. Commun. 299:2002;483-487
84. Koide Y., Hasegawa T., Takahashi A., Endo A., Mochizuki N., Nakagawa M., et al. Development of novel EDG3 antagonists using a 3D database search and their structure-activity relationships. J. Med. Chem. 45:2002;4629-4638
85. Kahan B.D., Karlix J.L., Ferguson R.M., Leichtman A.B., Mulgaonkar S., Gonwa T.A., et al. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation. 76:2003;1079-1084
86. Graler M.H., Goetzl E.J. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G protein-coupled receptors. Faseb J. 18:2004;551-553
87. Billich A., Bornancin F., Devay P., Mechtcheriakova D., Urtz N., Baumruker T. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J. Biol. Chem. 278:2003;47408-47415
88. Paugh S.W., Payne S.G., Barbour S.E., Milstien S., Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett. 554:2003;189-193
89. Sanchez T., Estrada-Hernandez T., Paik J.H., Wu M.T., Venkataraman K., Brinkmann V., et al. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J. Biol. Chem. 278:2003;47281-47290
90. Bittman R., Swords B., Liliom K., Tigyi G. Inhibitors of lipid phosphatidate receptors: N-palmitoyl-serine and N-palmitoyl-tyrosine phosphoric acids. J. Lipid Res. 37:1996;391-398
91. Liliom K., Bittman R., Swords B., Tigyi G. N-palmitoyl-serine and N-palmitoyl-tyrosine phosphoric acids are selective competitive antagonists of the lysophosphatidic acid receptors. Mol. Pharmacol. 50:1996;616-623
92. Hooks S.B., Ragan S.P., Hopper D.W., Honemann C.W., Durieux M.E., Macdonald T.L., et al. Characterization of a receptor subtype-selective lysophosphatidic acid mimetic. Mol. Pharmacol. 53:1998;188-194
93. Fischer D.J., Nusser N., Virag T., Yokoyama K., Wang D., Baker D.L., et al. Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol. Pharmacol. 60:2001;776-784
94. Ohta H., Sato K., Murata N., Damirin A., Malchinkhuu E., Kon J., et al. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol. Pharmacol. 64:2003;994-1005
95. Okusa M.D., Ye H., Huang L., Sigismund L., Macdonald T., Lynch K.R. Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemia-reperfusion injury. Am. J. Physiol. Renal. Physiol. 285:2003;F565-574
96. Yamada T., Sato K., Komachi M., Malchinkhuu E., Tobo M., Kimura T., et al. Lysophosphatidic acid in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J. Biol. Chem. 279:2004;6595-6605
97. Rother E., Brandl R., Baker D.L., Goyal P., Gebhard H., Tigyi G., et al. Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation. 108:2003;741-747
98. Zhang C, Baker DL, Yasuda S, Makarova N, Balazs L, Johnson LR, et al. Lysophosphatidic acid induces neointima formation through PPARg activation. J Exp Med 2004;199:763-74.
99. Arikawa K., Takuwa N., Yamaguchi H., Sugimoto N., Kitayama J., Nagawa H., et al. Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of cellular RAC activity. J. Biol. Chem. 278:2003;32841-32851
100. Ikeda H., Satoh H., Yanase M., Inoue Y., Tomiya T., Arai M., et al. Antiproliferative property of sphingosine 1-phosphate in rat hepatocytes involves activation of Rho via Edg-5. Gastroenterology. 124:2003;459-469
101. Ohmori T., Yatomi Y., Osada M., Kazama F., Takafuta T., Ikeda H., et al. Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc. Res. 58:2003;170-177
102. Kumar S., Tamura K., Jakobsen I.B., Nei M. MEGA2: molecular evolutionary genetics analysis software. Bioinformatics. 17:2001;1244-1245
103. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19:1998;1639-1662
104. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., et al. The Protein Data Bank. Nucleic Acids Res. 28:2000;235-242
105. Halgren T.A. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J. Comp. Chem. 17:1996;490-519
106. MOE. edition 2003.02. Edited by Montreal Chemical Computing Group; 2002.